Changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer

Tumori

Volumn 95, Issue 2, 2009, Pages 177-184

  Giovacchini, Giampiero ^a   Picchio, Maria ^b   Schipani, Stefano ^c   Landoni, Claudio ^a,b   Gianolli, Luigi ^b   Bettinardi, Valentino ^b   Muzio, Nadia Di ^c   Gilardi, Maria Carla ^a,b,d   Faziot, Ferruccio ^a   Messa, Cristina ^a,d  

^a SAN GERARDO HOSPITAL   (Italy)

^b Nuclear Medicine

^c SAN RAFFAELE HOSPITAL   (Italy)

^d CNR   (Italy)

Author keywords

Lung cancer; Positron emission tomography; Radiotherapy

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NAVELBINE;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONOTHERAPY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMAGE RECONSTRUCTION; IMAGING SYSTEM; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LYMPH NODE METASTASIS; PNEUMONIA; RADIATION DOSE; TREATMENT RESPONSE; TUMOR LOCALIZATION;

EID: 67649127036     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500208     Document Type: Article

References (37)

1. Abe Y, Matsuzawa T, Fujiwara T, Itoh M, Fukuda H, Yamaguchi K, Kubota K, Hatazawa 1, Tada M, Ido T, Watanuki S: Clinical assessment of therapeutic effects on cancer using '8F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. mt I Radiat OncolBiolPhys, 19: 1005-1010, 1990.
2. Hebert ME, Lowe VJ, Hoffman JM, Patz FE, Anscher MS: Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am I Clin Oncol, 19: 416-42 1, 1996.
3. Hicks RI, Kalif V, MacManus MP, Ware RE, ]\IcKenzie AI Matthews JP, Ball DL: The utility of (")F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. I NucI Med, 42:1605-1613, 2001.
4. MacManus MP, Hicks RI, Matthews IP, McKenzie A, Rischin D, Salminen EK, Ball DL: Positron emission tomography is superior to computed tomography scanning for response- assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. I Clin Oncol, 21: 1285-1292, 2003.
5. Cerfolio RI, Bryant AS, Winokur IS, Ohja B, Bartolucci AA: Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg, 78: 1903-1909, 2004.
6. Cerfolio RI, Ojha B, Mukherjee 5, Pask AR, Bass CS, Katholi CR: Positron emission tomography scanning with 2-fluo- ro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. I Thorac Cardiovasc Surg, 125: 938-944, 2003.
7. MacManus MP, Ricks RI, Matthews JP, Wirth A, Rischin D, Ball DL: Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer, 49: 95- 108, 2005.
8. Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, EberhardtW, Stamatis G, Gauler I, Antoch G, Bockisch A, Stuschke M: Value of '8F-fluoro-2-deoxy-D- glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res, 12:97-106,2006.
9. Alongi F, Ragusa P, Montemaggi P, Bona CM: Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non-small cell lung cancer. Tumori, 92: 327-333, 2006.
10. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Scheiderbauer J, Machulla HI, Dittmann H, Vonthein R, Bares R: Is standardised ('8)F-FDG uptake value an outcome predictor in patients with stage III non- small cell lung cancer? Eur I Nucl Med Mol Imaging, 33: 263-269, 2006.
11. Gagel B, Piroth M, Pinkawa M, Reinartz P, Krohn T, Kaiser HJ, Stanzel S, Breuer C, Asadpour B, Schmachtenberg A, Eble MI: Sequential (gemcitabine/ vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PETbased target volume definition in locally advanced non- small cell lung cancer: first results of a phase 1/11 study. BMC Cancer, 7: 112-122, 2007.
12. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK: Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small- cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol, 9:1193-1198, 1998.
13. Weber WA, Petersen V, Schmidt B, rndale-Hines L, Link T, Peschel C, Schwaiger M: Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. I Clin Oncol, 21: 2651-2657, 2003.
14. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Langen HI, Bares R: '8F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non- small cell lung cancer. Eur I NucI Med Mol Imaging, 34: 463-471, 2007.
15. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Dittmann H, Langen HJ, Bares R: Repeat 18F- FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 55: 165-171, 2007.
16. Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, De Mey I, De Greve 1: Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (('8)FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer, 62: 55-61, 2008.
17. Erdi YE, Macapinlac H, Rosenzweig KE, Humm IL, Larson SM, Erdi AK, Yorke ED: Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nuci Med, 27: 861-866, 2000.
18. van BaardwijkA, Bosmans G, DekkerA, van Kroonenburgh M, Boersma L, Wanders S, Oilers M, Houben R, Minken A, Lambin P, De Ruysscher D: Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol, 82: 145-152, 2007.
19. Hassaballa HA, Cohen ES, Khan AJ, Mi A, Bonomi P, Rubin DB: Positron emission tomography demonstrates radiation-induced changes to nonirradiated lungs in lung cancer patients treated with radiation and chemotherapy. Chest, 128: 1448-1452, 2005.
20. Ceresoli GL, Cattaneo GM, Castellone P, Rizzos G, Landoni C, Gregorc V, Calandrino R, Villa E, Messa C, Santoro A, Fazio F: Role of computed tomography and ['8Flfiuo- rodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung can- cer: a comparison with standard techniques with and without elective nodal irradiation. Tumori, 93: 88-96, 2007.
21. Young H, Baum R, Cremerius U, Herholz K, Hoekstra 0, Lammertsma AA, Pruim I, Price P: Measurement of clinical and subclinical tumour response using ['8F]-fluo- rodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer, 35: 1773-1782, 1999.
22. Hicks RI, MacManus MP, Matthews JR Hogg A, Binns D, Rischin D, Ball DL, Peters LI: Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Intl Radiat Oncol Biol Phys, 60: 412-418, 2004.
23. Mikhaeel NG: Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur I Nucl Med Mol Imaging, 33 (Suppl 1): 22-26, 2006.
24. Kostakoglu L, Coleman M, Leonard JP Kuji I, Zoe H, Goldsmith SI: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkins disease. I Nucl Med, 43:1018-1027, 2002.
25. Koukouraids MI, Giatromanolaki A, Sivridis E, Fezoulidis I:Cancer vascularization: implications in radiotherapy? Intl Radiat Oncol Biol Phys, 48: 545-553, 2000.
26. Miyamoto T, Ishii S, Eguchi-Kasai K, Koyama-Saegusa K: Radiosensitivity of hypoxic and proliferating clonogen in a human lung cancer grown in nude mice. Oncol Rep, 14: 1421-1428, 2005.
27. Gagel B, Reinartz P Demirel C, Kaiser HI, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble Ml: ['8F]fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non- small-cell lung cancer: a feasibility study. BMC Cancer, 6:51-58, 2006.
28. Gabriele P, Malinverni G, Moroni GL, Gatti M, Regge D,Versari A, Serafini D, Fraternali A, Salvo D: The impact of '8F- deoxyglucose positron emission tomography on tumor staging, treatment strategy and treatment planning for radiotherapy in a department of radiation oncology. Tumori, 90: 579-585, 2004.
29. Ramsey CR, Langen KM, Kupelian PA, Scaperoth DD, Meeks SL, Mahan SL, Seibert RM: A technique for adaptive image-guided helical tomotherapy for lung cancer. Int I Radiat Oncol Biol Phys, 64: 1237-1244, 2006.
30. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Par- mar M: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet, 350: 161-165, 1997.
31. Gagel B, Piroth M, Pinkawa M, Reinartz P Zimny M, Fischedilc K, Stanzel S, Breuer C, Skobel E, Asadpour B, SchmachtenbergA, Buell U, Eble MI: Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study. Strahlenther Onkol, 182: 263-269, 2006.
32. Rohren EM, Lowe VI: Update in PET imaging of nonsmall cell lung cancer. Semin Nucl Med, 34: 134-153, 2004.
33. Geets X, Daisne JF, Tomsej M, Duprez T, Lonneux M, Gregoire V: Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. Radiother Oncol, 78: 291-297, 2006.
34. Weber WA: PET for response assessment in oncology: radiotherapy and chemotherapy. Br I Radiol, 78 (Suppl 28): 42-49, 2005.
35. MacManus MP, Hicks RJ: Impact of PET on radiation therapy planning in lung cancer. Radiol Clin North Am, 45:627- 638, 2007.
36. Lowe VI, Hebert ME, Anscher MS, Coleman RE: Serial evaluation of increased chest wall F-18 fluorodeoxyglucose (FDG) uptake following radiation therapy in patients with bronchogenic carcinoma. Clin Positron Imaging, 1: 185- 191, 1998.
37. Lin P Delaney C, Chu J, Kiat H, Pocock N: Fluorine18 FDG dual-head gamma camera coincidence imaging of radiation pneumonitis. Clin Nuci Med, 25: 866-869, 2000.